Mental Health Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Panic Disorder
Barr receives approval for generic Xanax XR tablets for panic disorder
August 28th, 2006
Barr Laboratories, Inc., announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer, Inc.'s Xanax XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch its product immediately. Xanax XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia. Barr's Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the 12 months ending May 2006, according to IMS sales data. ...
Source: Mental Health Weekly Digest (2006-08-28)
|
